What effect does dysbiosis have on Enterobacteriaceae?
Enterobacteriaceae / Enterobacteria have the potential for overgrowth and intestinal domination during dysbiosis (1).
What are the effects of the increased abundance of Enterobacteriaceae?
A wide range of human diseases such as
- Inflammatory Bowel Disease (IBD) (2, 3, 4, 5),
- Colorectal Cancer (CRC) (6, 7),
- Necrotizing enterocolitis (8),
- Irritable Bowel Syndrome (IBS) (9, 10),
- Adiposity / obesity (11, 12)
are associated with a severe disruption of the balanced gut microbial ecosystem, often characterized by an expansion of facultative anaerobic Enterobacteriaceae (13).
What mechanism underlies the worsening of Inflammatory Bowel Disease (IBD) by Enterobacteriaceae?
Enterobacteriaceae exacerbates IBD by promoting inflammation through lipopolysaccharide (LPS)-mediated immune activation. LPS activates CD284 (Toll-Like Receptor 4 (TLR-4)) / MYD88 / NFKB signaling pathway, driving IL-17 and tissue damage (1).
References
(1) Costa et al. 2020 BMC Microbiol 20: 178
(2) Darfeuille-Michaud et al. 1998 Gastroenterology 115: 1405-1413
(3) Seksik et al. 2003 Gut 52: 237
(4) Gophna et al. 2006 J. Clin. Microbiol. 44: 4136
(5) Morgan et al. 2012 Genome Biol 13: R79
(6) Swidsinski et al. 1998 Gastroenterology.115: 281–6
(7) Martin et al. 2004 Gastroenterology 127: 80
(8) Hunter et al. 2008 Pediatr Res. 63: 117
(9) Krogius-Kurikka et al. 2009 BMC Gastroenterol. 9: 95
(10) Gobert et al. 2016 Sci. Rep. 6: 39399
(11) Devkota et al. 2012 Nature 487: 104
(12) Fei & Zhao 2013 ISME J. 7: 880
(13) Shin et al. 2015 Trends Biotechnol 33: 496
see also:
Enterobacteriaceae / Enterobacteria & Inflammatory Bowel Disease (IBD)
Chemotherapy (CT)-induced gastrointestinal toxicity
